[A24-35] Idecabtagene vicleucel (multiple myeloma, at least 2 prior therapies) – Benefit assessment according to §35a Social Code Book V
Last updated 19.09.2024
Project no.:
A24-35
Commission:
Commission awarded on 02.04.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with relapsed and refractory multiple myeloma who have received prior therapies and have demonstrated disease progression on the last therapy; pretreatment includes an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody
- Patients with 2 to 3 prior therapies: added benefit not proven
- Patients with at least 4 prior therapies: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A24-35_en
| Project no. | Title | Status |
|---|---|---|
| A24-28 | Idecabtagene vicleucel (multiple myeloma, at least 3 prior therapies) – Benefit assessment according to §35a Social Code Book V | Withdrawn commission |
| G22-01 | Idecabtagene vicleucel (multiple myeloma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |
| A24-81 | Idecabtagene vicleucel (multiple myeloma, at least 2 prior therapies) – Addendum to Project A24-35 | Commission completed |
Federal Joint Committee (G-BA)
2024-09-18 A G-BA decision was published.